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Abstract
Background: Previous studies identified CD147 as the chemotactic receptor on inflammatory leukocytes for
extracellular cyclophilins (eCyp). However, CD147 is not known to associate with signal transducing molecules, so
other transmembrane proteins, such as proteoglycans, integrins, and CD98, were suggested as receptor or co-
receptor for eCyp. CD147 is ubiquitously expressed on many cell types, but relationship between the level of CD147
expression and cellular responses to eCyp has never been analyzed. Given the role of eCyp in pathogenesis of many
diseases, it is important to know whether cellular responses to eCyp are regulated at the level of CD147 expression.
Results: Here, we manipulated CD147 expression levels on HeLa cells using RNAi and investigated the signalling
and chemotactic responses to eCypA. Both Erk activation and chemotaxis correlated with the level of CD147
expression, with cells exhibiting low level expression being practically unresponsive to eCypA.
Conclusions: Our results provide the first demonstration of a chemotactic response of HeLa cells to eCypA,
establish a correlation between the level of CD147 expression and the magnitude of cellular responses to eCypA,
and indicate that CD147 may be a limiting factor in the receptor complex determining cyclophilin-induced Erk
activation and cell migration.
Background
Leukocyte trafficking and recruitment is a critical compo-
nent of inflammation-mediated pathology. The main reg-
ulators of leukocyte trafficking are chemokines, a family
of chemoattracting cytokines that control cell migration
and adhesion [1]. However, other factors, in particular
extracellular cyclophilins (eCyp), also induce potent che-
motactic responses of immune cells (reviewed in [2]). We
[3-6] and others [7,8] have observed that secreted cyclo-
philin A (CypA) is a potent leukocyte chemoattractant in
vitro and in vivo.
In studies aimed at establishing the mechanism whereby
cyclophilins mediate their chemotactic activity, our group
identified CD147 (also known as EMMPRIN and basigin),
as the signalling receptor for eCyp [3,9]. Indeed, all human
[3,6] and mouse [4,5] leukocytes examined to date require
expression of CD147 for cyclophilin-dependent chemo-
taxis to occur. However, CD147 is not known to mediate
signal transduction events, suggesting that other molecule
(s) associated with CD147 may function as a signal-trans-
ducing co-receptor. Consistent with this notion, trunca-
tion of the cytoplasmic tail of CD147 does not abolish
signalling response to eCypA [10]. The possibility of addi-
tional co-receptor is also supported by inability of eosino-
phils to respond to eCypA despite the fact that these cells
express relatively high levels of CD147 [5]. Such signal-
transducing activity may be exerted by known CD147-
interacting proteins, such as b1 integrins [11,12], CD98
[13], and syndecan-1 [14], which may function as a multi-
molecular receptor complex [13]. Whether and how the
level of CD147 expression influences activity of this com-
plex is unknown. We recently reported that activated CD4
+ T cells showed enhanced cyclophilin-mediated chemo-
taxis relative to resting T cells, that correlated with an
upregulated expression of CD147 [5,6], but cell activation
likely increases expression of many other proteins, includ-
ing those that may be involved in eCyp-induced signalling,
thus precluding reliable interpretation of this result.
The chemotactic activity of CD147 has been investi-
gated until now only for inflammatory leukocytes.
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present on almost all studied cell types, including cancer
cells and stem cells [15,16], suggesting that eCyp-
induced chemotaxis may underlie such processes as
metastasis or cell development. An important question
in this regard is whether such response depends on the
level of CD147 expression. In this study we investigated
cyclophilin-induced chemotactic activity of HeLa cells
manipulated by RNAi technology to express varying
levels of CD147. Our results demonstrate a direct corre-
lation between CD147 expression and signalling and
chemotactic responses to eCypA, suggesting that CD147
may be a rate-limiting component in the eCypA-
responding receptor complex.
Methods
RNA interference and CD147 knockdown
siRNA (small interfering RNA) was derived from the
nucleotide sequence of CD147 [17] corresponding to
nucleotides 470-490. Forward 5’-GATCCCCcggctccgagag-
caggttcttcaagagagaacctgctctcggagccgTTTTTGGAAA-3’
and reverse 5’-AGCTTTTCCAAAAAcggctccgagagcagg
ttctctcttgaagaacctgctctcggagccgGGG-3’ complementary
oligonucletides containing the above sequence were
designed according to protocol recommended for pSU-
PER.retro.puro expression system (OligoEngine, Seattle,
WA) by the manufacturer. A mixture of both oligonucleo-
tides (3 μg of each) was incubated in 50 μlo f1 0 0m M
NaCl and 50 mM HEPES pH 7.4 at 90°C for 4 min, and
then at 70°C for 10 minutes. The mixture was then cooled
down to 10°C over a period of 50 minutes. pSUPER.retro.
puro vector was linearized by subsequent cleavage with
HindIII and BglII. Annealed nucleotides were ligated into
the linearized pSUPER.retro.puro using T4 ligase as
recommended by the OligoEngine protocol creating pSu-
per3,4 construct. E. coli Stbl 2 competent cells (Invitrogen)
were transformed with pSuper3,4 and ampicillin resistant
colonies were isolated and amplified.
Purified pSuper3,4 plasmid as well as pSuper empty vec-
tor were used for transfection of exponentially growing
HeLa-CD4 [18] cells. Puromycin resistant cells were exam-
ined for CD147 expression by flow cytometry. pSuper3,4-
transformed cell population was further enriched for cells
with downregulated CD147 surface expression by removal
of cells with higher CD147 expression using magnetic
beads with conjugated anti-CD147 antibodies (Ancell,
Bayport, MN). Remaining cell population was expanded,
sorted on a flow cytometer, and several cell clones with
low CD147 expression were established.
Reagents
FITC-conjugated anti-CD147 mouse monoclonal anti-
body was purchased from Ancell. FITC-conjugated
mouse IgG1 was obtained from PharMingen (BD
Biosciences, San Jose, CA). Human recombinant cyclo-
philin A was purchased from Calbiochem (EMD, Rock-
l a n d ,M A ) .H u m a nS D F - 1 a was purchased from
Peprotech (Rocky Hill, NJ). The primary anti-phospho-
Erk1/2 rabbit monoclonal antibody (recombinant clone
AW39R) was purchased from Millipore (Billerica, MA),
rabbit polyclonal antibody to Erk1/2 was from Cell Sig-
nalling Technology (Boston, MA), and the secondary
antibody, anti-rabbit IgG (Horseradish Peroxidase linked
F(ab)2 fragment), was from GE Healthcare, UK.
In vitro chemotaxis assay
Chemotactic activity was assessed using 48-well modified
Boyden chambers (Neuro Probe Inc., Gaithersburg, MD)
with the two compartments separated by an 8 μm polyvi-
nylpyrrolidone free polycarbonate membrane (Neuro
Probe Inc.). HeLa-CD4 cells [18], at 10
4 cells/well in
RPMI-1640 culture medium supplemented with 1% BSA,
Cohn Fraction V (Sigma-Aldrich, St. Louis, MO), were
added to the upper compartment (40 μl volume) and med-
ium containing recombinant human CypA (100 ng/ml) or
SDF-1a (50 ng/ml) or medium alone (25 μl) was added to
the lower compartment. The chambers were incubated for
50 minutes at 37°C. Then the membrane was removed,
nonmigrated cells were scrapped off the upper side with
PBS, and the membrane, after drying, was stained with
Wright-Giemsa (Camco, Fort Lauderdale, FL) to reveal
bound cells. A chemotaxis index was calculated for each
test well by dividing the number of cells counted for that
well by the number of cells counted in media wells.
Flow cytometry
Cells were stained with 10 μg/ml of FITC-conjugated
anti-human CD147 mAb (Ancell, Bayport, MN) or FITC-
IgG1 isotype control mAb for 15 min at 4°C, washed with
cold PBS and used for analysis. Flow cytometric analysis
was done using a FACSCalibur instrument and CellQuest
Pro software (Becton Dickinson, San Jose, CA). To ana-
lyze the staining of CD147, cells were first gated by for-
ward and side scatter. Live cell populations were gated
upon on an acquisition plot and 20,000 events were col-
lected from this region. An acquisition histogram plot
was also assessed for this region using parameter 3, the
FL-1 detector, set to Log mode in order to detect fluores-
cence of the green fluorophore, FITC. The voltage of the
parameter was adjusted to the relative fluorescence inten-
sity of the high CD147 expressing cell line. All subse-
quent samples were acquired using the same settings.
Isotype-stained cells were used as control; background
staining was less than 1%.
Signalling analysis
Serum-starved 5 × 10
6 HeLa-CD4 cells were pre-treated
with CypA (100 ng/ml) or PMA (100 nM), and incubated
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Laemmli sample buffer (BioRad, Hercules, CA), sonicated
for 5-7 seconds to shear DNA and reduce sample viscos-
ity, separated on 10-20% SDS-PAGE and subjected to
Western blotting analysis using anti-p44/p42 MAPK
antibody and anti-phosphorylated-p44/p42 pMAPK
antibody.
Statistical analysis
Data are presented as mean ± S.E.M. Statistical analysis
was performed using Student’st - t e s ta n dp<0 . 0 5w a s
considered significant.
Results and discussion
To manipulate CD147 expression levels on HeLa cells we
used the RNAi knockdown approach. HeLa-CD4 (MAGI)
cells were transfected with the pSuper-retro vector (Oli-
goEngine, Seattle, WA) containing puromycin resistance
gene and siRNA corresponding to the nucleotides 470-490
of CD147 mRNA. Puromycin resistant cells displayed
lower concentrations of surface CD147 than parental cell
line. The cells with the highest CD147 surface expression
were removed using magnetic beads followed by flow
cytometric cell sorting of remaining cells. Cell clones with
decreased CD147 abundance were established from the
remaining cell population. Cell clones with low and med-
ium CD147 expression were selected for further analysis
in comparison to original HeLa-CD4 cell clones trans-
duced with an empty vector (high level CD147 expressors)
(Figure 1A). Importantly, the level of expression changed
after several passages of cells, making it necessary to verify
the expression level before each experiment.
Using HeLa-CD4 cells transduced with an empty vector,
w ef i r s tp e r f o r m e dad o s er e s p o n s ea n a l y s i st oi d e n t i f y
the optimal concentration of CypA needed to induce
chemotaxis. The concentration inducing maximal chemo-
tactic response was 100 ng/ml and was used in all subse-
quent experiments. A good correlation between the level
of CD147 expression and the chemotactic response of the
cells to CypA was observed, with significant differences in
chemotactic index between low, medium, and high expres-
sing cells (Figure 1B). The observed chemotactic response
was dependent on CD147 as it was completely blocked
when anti-CD147 mAb was added to the cells in the
upper chamber. Increased cell migration was not due to
chemokinesis, as no migration was observed when CypA
was added to both chambers of the Boyden chamber
assembly. Importantly, the level of CD147 expression did
not affect the ability of cells to migrate in response to
SDF-1a (Figure 1C), thus excluding the possibility that
low CD147 adversely and non-specifically affected cell
mobility. In fact, cells with low CD147 expression
migrated to SDF-1a better than high-CD147-expressing
cells. This result may reflect some antagonism between
these two receptors, suggested also by their opposing reac-
tion to TCR activation in T lymphocytes [19]. These
results are consistent with previously observed correlation
between CD147 expression and CypA-induced chemotaxis
of CD4+ T cells [6], however, in contrast to that previous
study where activated and non-activated T cells were com-
pared, siRNA treatment of the cells in this study is unlikely
to affect expression of other than CD147 molecules, thus
excluding the possibility that observed differences are due
to altered expression of another signalling molecule
involved in response to eCypA. Our data also indicate that
a certain minimal level of CD147 expression is required
for chemotactic response of cells to cyclophilin.
Cell chemotaxis is dependent on signalling events
transduced by the chemotactic receptor in response to
ligand binding. Interaction of cyclophilin with CD147
induces a number of signalling events, including Ca
2+
mobilization and Erk 1/2 activation [3,9]. We analyzed
CypA-induced Erk activation in HeLa cells expressing
low and high levels of CD147. Consistent with results of
the chemotaxis assay, cells with high level of CD147
expression exhibited Erk phosphorylation whereas Erk
activation in cells with low level CD147 expression was
minimal (Figure 2). Both high and low CD147 expressors
equally responded to PMA activation, indicating that low
response to eCypA was not due to an internal signalling
defect. Despite the fact that the antibodies we used
recognize both p42 and p44 forms of Erk, only one Erk
form was detected in these experiments. This result may
reflect the feature of the HeLa cell line where Erk 1 is
expressed at a much lower level than Erk 2 [20]. This
result establishes a correlation between the level of
CD147 expression and Erk activation in response to
eCypA stimulation.
Overall, results of this study provide evidence for the fol-
lowing two important features of the cellular responses to
extracellular CypA. First, the response depends on the
level of CD147 expression. Low CD147 expressing cells
respond poorly to eCypA by chemotaxis or Erk activation.
This dependence of response on CD147 abundance may
be due to simple cumulative property of the signalling
events, but may also reflect different modes of interaction
between the ligand and receptor. For example, CD147,
when present at low density on the cell surface, may not
form homo-oligomers [21]. Although requirement of
CD147 oligomerization for CypA-induced signalling has
not been established, there is ample evidence for oligomer-
ization of other chemotactic receptors [22-24]. Oligomeri-
zation of CD147 may be required to allow eCypA make
contact with Proline 211 at the border of the transmem-
brane and ectodomain of CD147, which is the target of
isomerase activity of CypA [25]. In any case, this result
suggests that CD147 is the rate-limiting component of the
multimeric receptor complex responding to eCypA.
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the chemotaxis-inducing activity of eCypA is not limited
to leukocytes but likely extends to any cell type expres-
sing sufficient levels of CD147. This feature would be
especially relevant to cancer cells, which are known to
express high CD147 levels (reviewed in [26]). CypA-
induced chemotaxis may be an important contributor to
metastatic activity of cancer cells. Correspondingly, tar-
geting CD147 expression level may be a valid therapeu-
tic approach aimed at reducing metastatic activity. One
of the key regulators of the level of plasma membrane
expression of CD147 is Cyp60 [27,28], a member of the
cyclophilin family of proteins [29]. Expression of this
protein in various cells has not been characterized, but
may be an important factor determining cellular
responses to eCyp and a potential target for therapeutic
interventions. Another potential type of effector cells
responsive to extracellular CypA are stem cells [15].
Additional studies are required to correlate the level of
A
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Figure 1 CD147 expression and chemotactic activity. HeLa-CD4 cells stably transfected with anti-CD147 siRNA-expressing vector or empty
vector control were sorted according to the level of CD147 expression into low, medium and high (cells transfected with empty vector)
expressing clones (A). Chemotactic activity of the clones in response to CypA (B) or SDF-1a (C) was measured as described in Materials and
Methods. Chemotactic activity was analyzed in triplicate and results are presented as mean ± SEM, *p < 0.05; **p < 0.01; ***p < 0.001. Results
are shown for one representative experiment out of two performed.
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Figure 2 Analysis of Erk activation. Cells with low and high levels
of CD147 expression were stimulated (A) or not (C) with CypA or
PMA as described in Materials and Methods. Phosphorylated
(activated) and total Erks were revealed by Western blotting. Results
are presented for one representative experiment out of three
performed.
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motactic activity or other responses.
Conclusions
Results of the current study provide the first demonstra-
tion of the chemotactic activity of HeLa cells to eCypA.
They also establish a direct correlation between cellular
chemotactic and signalling responses to extracellular
cyclophilin A and the level of CD147 expression, suggest-
ing that CD147 is the rate-limiting factor in the receptor
complex responding to eCyp. These findings provide a
strong rationale for investigating regulators of CD147
expression, which may be targeted to moderate eCyp-
induced cellular responses in inflammatory diseases and
metastatic activity of cancer cells.
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